Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15028555
Gao N, et al. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287, C281-91 15028555
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

S780-p - Rb (human)
Modsite: strPPtLsPIPHIPr SwissProt Entrez-Gene
Orthologous residues
Rb (human): S780‑p, Rb (mouse): S773‑p, Rb (rat): S772‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

S795-p - Rb (human)
Modsite: sPykFPssPLrIPGG SwissProt Entrez-Gene
Orthologous residues
Rb (human): S795‑p, Rb (mouse): S788‑p, Rb (rat): S787‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

S807-p - Rb (human)
Modsite: PGGNIyIsPLksPyk SwissProt Entrez-Gene
Orthologous residues
Rb (human): S807‑p, Rb (mouse): S800‑p, Rb (rat): S799‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase

S811-p - Rb (human)
Modsite: IyIsPLksPykIsEG SwissProt Entrez-Gene
Orthologous residues
Rb (human): S811‑p, Rb (mouse): S804‑p, Rb (rat): S803‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  A2780 (ovarian), OVCAR3 (ovarian)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 decrease
LY294002 serum inhibit treatment-induced increase
rapamycin decrease
rapamycin serum inhibit treatment-induced increase